07:12am Sunday 24 September 2017

Dendritic cells control lymphocyte entry into lymph nodes

This is what Christine Moussion and Jean-Philippe Girard(1), researchers at the Institut de Pharmacologie et de Biologie Structurale (CNRS/Université de Toulouse III – Paul Sabatier) showed in a study(2) published online in the journal Nature on November 13, 2011. A better understanding of this process could lead to major applications in the treatment of chronic inflammatory diseases and cancer.

To fight viral and bacterial infections, circulating white blood cells called lymphocytes make their way towards the lymph nodes(3). They enter the lymph nodes through specialized blood vessels, called HEVs. These vessels are a very efficient port of entry since at least five million lymphocytes are estimated to enter the lymph nodes every second.

For a number of years, the team led by Jean-Philippe Girard, Senior researcher at Inserm, strived to better understand how a normal blood vessel becomes an HEV vessel (and vice versa). By studying cells near HEVs, the researchers from Toulouse have now identified the fundamental role of dendritic cells in the development of these venules. These star-shaped cells use their long processes to interact with blood vessels and deliver the required signal for these vessels to become HEVs. Dendritic cells help blood vessels, which formed an impassable barrier to the entry of lymphocytes, acquire the ability to let those enter massively into the lymph nodes. This process is key to the body’s immune surveillance.

Indeed, dendritic cells, which are known for their role as sentinels of the immune system, collect and present foreign antigens from viruses, bacteria or tumor cells to T lymphocytes. Furthermore, by controlling the entry of lymphocytes into lymph nodes via HEVs, dendritic cells allow lymphocytes to interact with the foreign antigens against which they are directed. These findings reveal that dendritic cells play an essential and previously unsuspected role in the immune system.

The researchers also studied the mechanisms involved in the cross-talk between dendritic cells and HEVs. A better understanding of these mechanisms could result in important applications in the treatment of chronic inflammatory diseases and cancer. Indeed, the development of HEVs has been observed in most chronic inflammatory conditions (rheumatoid arthritis, Crohn’s disease, atopic dermatitis, psoriasis, asthma, etc), contributing to tissue inflammation. Therefore, inhibiting HEV development could contribute to the reduction of inflammation. Conversely, by facilitating the entry of killer lymphocytes into tumor cells, HEVs may have a beneficial effect in cancer. Shedding light on the mechanisms underlying the development of HEVs could help generate more of these venules within tumors and therefore improve the eradication of cancer cells by killer lymphocytes.

Visualization of HEVs in a lymph node


© Jean-Philippe GIRARD-IPBS (CNRS/Université de Toulouse)

Visualization of HEVs (green) in a lymph node, using multiphoton microscopy. The other blood vessels are colored in red. HEVs allow entry of circulating lymphocytes into the lymph node.


Notes:

1 – Senior researcher at Inserm.
2 – This work was financially supported by the Ligue Nationale Contre le Cancer (Équipe labellisée Ligue 2009 to JPG), Association pour la Recherche contre le Cancer (ARC) and Foundation RITC (doctoral and post-doctoral fellowships).
3 – Lymph nodes support the proliferation and differentiation of immune cells. Lymphatic vessels carry a foreign antigen (often derived from a pathogen) from the tissue to the lymph nodes, triggering a specific immune response by activating T and B lymphocytes.

References:

Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Christine Moussion and Jean-Philippe Girard. Nature, November 2011, DOI: 10.1038/nature10540

Contact information:

CNRS Researcher
Jean-Philippe Girard
T +33(0) 6 03 70 64 88 / +33(0) 5 61 17 59 18 l Jean-Philippe.Girard@ipbs.fr

CNRS Press Office
Laetitia Louis
T +33(0) 1 44 96 51 51 l presse@cnrs-dir.fr


Share on:
or:

Health news